Healthcare
Live Price
Offline$21.33
+0.00% today
Window Change
-11.13%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RaySearch Laboratories AB (publ) (RSLBF) is a Healthcare stock with a market cap of $6.51B and listed on OTC. The stock last traded around $21.33 and down 11.1% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +12.8%, EPS growth of +12.0%, a dividend yield of 0.0%. What stands out right now is revenue +12.8%, EPS +12.0%, free cash flow -40.6% with operating margin 21.6% and ROIC 14.4%. Valuation sits in the middle of the pack at P/E 29.0 and price/sales 5.0. Stock Foundry combines RSLBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RSLBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RSLBF Max Drawdown
-11.13%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RSLBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$641.7M
-23.9% YoY
FY Net Income
-$47.3M
-299.0% YoY
Free Cash Flow
-$17.1M
-113.6% YoY
Revenue Growth
+12.8%
EPS Growth
+12.0%
Gross Margin
81.4%
Net Margin
17.2%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.3B | 1.2B | 1.0B | 844M | 642M |
| Gross Profit | 1.2B | 1.1B | 916M | 749M | 591M |
| Operating Income | 292M | 260M | 115M | 43M | -53M |
| EBITDA | 292M | 571M | 406M | 341M | 197M |
| Net Income | 228M | 204M | 82M | 24M | -47M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 407M | 463M | 344M | 160M | 103M |
| Total Assets | 2.0B | 2.1B | 2.0B | 1.9B | 1.7B |
| Total Liabilities | 1.0B | 1.2B | 1.2B | 1.2B | 1.1B |
| Shareholder Equity | 985M | 877M | 735M | 657M | 628M |
| Total Debt | 395M | 472M | 529M | 555M | 561M |
| Net Debt | -13M | 9M | 186M | 395M | 459M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
238M
-33.2% YoY
Capital Expenditures
255M
-10.2% YoY
Free Cash Flow
17M
-113.6% YoY
Key ratios
Gross Margin
81.4%
Operating Margin
21.6%
Net Margin
17.2%
ROE
23.6%
Debt / Equity
0.36x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.